Skip to main content
. Author manuscript; available in PMC: 2016 Dec 1.
Published in final edited form as: Cancer Prev Res (Phila). 2015 Oct 15;8(12):1131–1137. doi: 10.1158/1940-6207.CAPR-14-0274-T

Table 2.

Treatment-related Adverse Events

Treatment Subject AE (grade)
Placebo 1 ELEVATED SERUM AST (1)
2 MILDLY ELEVATED AST (1)
3 ELEVATED SERUM ALT (1), ELEVATED SERUM ALT (1), ELEVATED SERUM AMYLASE (2)
4 ELEVATED SERUM AST (1)
Poly E 200 mg 5 NAUSEA (1), HYPOTHYROIDISM (2)
6 BELCHING (1)
7 BELCHING (1)
Poly E 400 mg 8 NAUSEA (2), VOMITING (2)
9 ELEVATED SERUM ALK PHOS (1),
10 ELEVATED SERUM LDH (1), NAUSEA (1)
Poly E 600 mg 11 DIARRHEA (1), GAS (1), NAUSEA (1; 2 AEs), SOUR TASTE (1; 2 AEs), STOMACH DISCOMFORT (1), STOMACH PAIN (1), LOSS OF ENERGY (2)
12 ELEVATED SERUM AST (1)
13 ELEVATED SERUM LDH (1)